The aim of the study is to assess the effect of specific immunotherapy (SIT) to dust mites on clinical symptoms, reliever drugs usage, inhaled glucocorticosteroid usage, quality of life, lung function, chosen markers of inflammation, induction of regulatory lymphocytes, bronchial hyperreactivity with methacholine, and presence and type of allergy after two years of SIT in children with asthma.
Specific immunotherapy is the only one causal treatment method of atopic diseases including bronchial asthma in children. The aim of the study is to assess the effect of specific immunotherapy (SIT) to dust mites on clinical symptoms,reliever drugs usage, inhaled glucocorticosteroid usage, quality of life, lung function, chosen markers of inflammation, induction of regulatory lymphocytes, bronchial hyperreactivity with methacholine, and presence and type of allergy after two years of SIT in children with asthma.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
80
subcutaneous immunotherapy (House Dust Mites)
placebo of subcutaneous immunotherapy (House Dust Mites)
Department of Pediatrics and Allergy, Medical University of Lodz
Lodz, Poland
RECRUITINGclinical symptoms, reliever drugs usage, controller medication usage, quality of life, lung function, chosen markers of inflammation (ECP, specific IgE, specific IgG) induction of regulatory lymphocytes (Treg) - Foxp3 mRNA expression
Time frame: baseline (first visit), after 3 months (second visit), 12 months (third visit), 24 months (fourth visit)
bronchial hyperreactivity with methacholine, and presence and type of allergy after two years of SIT (skin prick tests)
Time frame: after 24 months from first visit (fourth visit)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.